Clinical trial NCT04601532
Conditions: Superficial Partial Thickness Burn
Sponsor: J. Peter Rubin, MD
Start date: 2021-06-11; Completion date: 2022-12-08
Enrollment: 26 participants; Allocation: RANDOMIZED; Intervention model: PARALLEL

Brief summary:
This study is an investigator initiated, single site, University of Pittsburgh, prospective, parallel group, randomized controlled trial comparing SynePure Wound Cleanser and Catasyn Advanced Technology Hydrogel (intervention group) to the current gold standard treatment Silvadene (control group). Both groups will receive the same care other than the treating agent. Subjects will be recruited form the UPMC Mercy Burn Center adult patient pool who have sustained superficial partial-thickness burn wounds that comprise less than or equal to 10% of total body surface area (TBSA)

Detailed description:
Current effective dressings for burn wounds contain silver (nanoparticulate or ionic), hypochlorite, hydrogen peroxide, sulfa agents, chlorhexidine, iodine or other dilute antiseptics meant to provide some measure of antimicrobial protection. However, all of these materials have some proven limitations in facilitating wound healing and also have notable local and systemic adverse effects. None of the current clinical treatments enhance healing and/or reduce scar formation. The purpose of this study is to test the safety and effectiveness of SynePure™ Wound Cleanser when used in combination with Catasyn™ Advanced Technology Hydrogel for the treatment of superficial partial-thickness burn wounds.

Arms: arm 1: Topical management via dressings provide a barrier against microbial infection. The current gold standard for burn wound dressings is silver (nanoparticulate or ionic), and it has shown some efficacy in treating infections, but it does not demonstrate an ability to prevent infections and some treatment guidelines even recommend against its use. Although silver dressing is preferred for military use, a retrospective review spanning 10 years of use in military environments showed that silver was not more effective than other antimicrobial topical treatments, and a meta-analysis with over 2500 surgical patients found silver sulfadiazine was associated with increased infection rates and hospital length-of-stays were two days longer on average. arm 2: Synedgen has developed Catasyn™ Advanced Technology Hydrogel and SynePure™ Wound Cleanser. These products are Food and Drug Administration (FDA) 510(k) cleared wound care medical devices, formulated with a novel biocompatible chitosan derivative, poly (acetyl, arginyl) glucosamine. SynePure™ Wound Cleanser is optimized for the cleansing and debridement of wounds and thermal injuries, and Catasyn™ Advanced Technology Hydrogel serves as a protective gel dressing. Together, these products reduce inflammation in wounds, aggregate bacteria and disrupt bacterial biofilms, and accelerate healing.
Interventions: intervention 1: Catasyn™ Advanced Technology Hydrogel and SynePure™ Wound Cleanser intervention 2: Silver Sulfadiazine
Intervention descriptions: intervention 1: Catasyn™ Advanced Technology Hydrogel is a wound hydrogel that provides a moist wound environment. A moist wound environment is supportive to wound healing. SynePure™ Wound Cleanser is a non-cytotoxic wound cleanser for the removal of foreign material from epidermal and dermal wounds, burns, cuts, abrasions and minor irritations of the skin. intervention 2: Silver sulfadiazine, a sulfa drug, is used to prevent and treat infections in burn wounds.

Protocol documents:
Prot_SAP_ICF_000.pdf: 
 
            
                             
 
1
 
 
 
NCT number: 
NCT04601532 
 
Official Title: Randomized Controlled Trial Assessing a Novel Glycopolymer Compound in 
the Treatment of Superficial Partial-Thickness Burns 
 
Study Protocol Document Date: 8/17/2020 
 
 
 
 


 
            
                             
 
2
TITLE:  Randomized controlled trial assessing a novel glycopolymer compound in the treatment of 
superficial partial-thickness burns. 
 
Abstract:  Current effective dressings for burn wounds contain silver (nanoparticulate or ionic), 
hypochlorite, hydrogen peroxide, sulfa agents, chlorhexidine, iodine or other dilute antiseptics meant 
to provide some measure of antimicrobial protection. However, all of these materials have some 
proven limitations in facilitating wound healing and also have notable local and systemic adverse 
effects.  None of the current clinical treatments enhance healing and/or reduce scar formation. The 
purpose of this study is to test the safety and effectiveness of SynePure™ Wound Cleanser when 
used in combination with Catasyn™ Advanced Technology Hydrogel for the treatment of superficial 
partial-thickness burn wounds. 
 
This study is an investigator initiated, single site, University of Pittsburgh, prospective, parallel group, 
randomized controlled trial comparing SynePure Wound Cleanser and Catasyn Advanced 
Technology Hydrogel (intervention group) to the current gold standard treatment Silvadene (control 
group). Both groups will receive the same care other than the treating agent. Subjects will be recruited 
from the UPMC Mercy Burn Center adult patient pool who have sustained superficial partial-thickness 
burn wounds that comprise ≤10% of total body surface area (TBSA). 
 
1.0 Objective and Specific Aims: 
Primary Objective: To test the effectiveness of SynePure Wound Cleanser when used in 
combination with Catasyn Advanced Technology Hydrogel for the treatment of superficial partial-
thickness burn wounds as compared to standard of care treatment.  
 
Secondary Objective: To test the ongoing safety of SynePure Wound Cleanser when used in 
combination with Catasyn Advanced Technology Hydrogel for the treatment of superficial partial-
thickness burn wounds as compared to standard of care treatment.  
 
Hypothesis: SynePure Wound Cleanser when used in combination with Catasyn Advanced 
Technology Hydrogel is safe in humans and improves time to heal and infection rates in superficial 
partial-thickness burn wounds when compared to standard of care treatment.  
 
Specific Aims:  
1) Compare re-epithelialization rates between treatment groups. 
2) Compare rates of infection, complication and progression of the wound to deep partial/full 
thickness between treatment groups. 
3) Compare healed wound characteristics, Patient Reported Outcomes and Health-related 
Quality of Life Outcomes between treatment groups.  
 
2.0 Background and significance:  
2.1 Background:  
Burn wounds are associated with significant morbidity and mortality as well as Quality of Life 
impairments for the patient. Burn wounds can be particularly problematic as they can 
compromise skin integrity potentially allowing microbial invasion and subsequent infection.  In 
fact, thermal destruction of the skin provides an ideal environment for microbial colonization.1 If 
left untreated, the infection can spread to a systemic level, further jeopardizing the patient.  
 
Topical management via dressings provide a barrier against microbial infection. The current 
gold standard for burn wound dressings is silver (nanoparticulate or ionic) and it has shown 
some efficacy in treating infections but it does not demonstrate an ability to prevent 
infections and some treatment guidelines even recommend against its use.2-3 Although 
silver dressing is preferred for military use, a retrospective review spanning 10 years of use 


 
            
                             
 
3
in military environments showed that silver was not more effective than other antimicrobial 
topical treatments4 and a meta-analysis with over 2500 surgical patients found silver 
sulfasalazine was associated with increased infection rates and hospital length-of-stays 
were two days longer on average.5  
 
Other current effective dressings for burn wounds include hypochlorite, hydrogen peroxide, 
sulfa agents, chlorhexidine, iodine or other dilute antiseptics meant to provide some 
measure of antimicrobial protection. However, all of these have some proven limitations in 
facilitating wound healing and also have notable local and systemic adverse effects (see ref 
6 for review). Finally, none of the current clinical treatments, have demonstrated evidence 
of enhanced healing and/or reduced scar formation. 
 
Synedgen has developed SynePure Wound Cleanser and Catasyn Advanced Technology 
Hydrogel. These products are Food and Drug Administration (FDA) 510(k) cleared wound 
care medical devices formulated with a novel biocompatible chitosan derivative, poly 
(acetyl, arginyl) glucosamine. SynePure is optimized for the cleansing and debridement of 
wounds and thermal injuries, and Catasyn serves as a protective gel dressing. Together, 
these products reduce inflammation in wounds, aggregate bacteria and disrupt bacterial 
biofilms, and accelerate healing. SynePure and Catasyn are nontoxic, biocompatible, shelf-
stable up to two years, easy to use, and may be used in any care setting from the battlefield 
to a tertiary hospital. 
 
Synedgen optimized Catasyn’s formulation, completed GLP biocompatibility studies, and 
performed engineering and qualification runs for in-house cGMP manufacturing of the 
product. Catasyn’s constituent glycopolymer preparation was optimized and validated under 
cGMP. Together with collaborators at the University of Miami, the studies necessary to 
determine the optimized schedule for the treatment of full-thickness burns were completed. 
Work done in collaboration with the University of Pittsburgh Medical Center further 
established the efficacy of SynePure and Catasyn’s efficacy in a pig model of infected 
thermal injury. In this study, using SynePure and Catasyn together twice a day, three days 
a week demonstrated 4-6 day faster healing of methicillin-resistant Staphylococcus aureus  
burns through reduced infection, increased epithelialization, and faster wound closure as 
compared to standard of care (Silvadene).7 Similar results were observed in partial 
thickness injury infected with Pseudomonas aeruginosa.8  
 
We have also explored SynePure and Catasyn’s activity by gene array analysis to better 
understand the gel’s capacity to accelerate healing and control inflammation. Confirmation 
of SynePure and Catasyn’s reduction in wound bacterial colonization was confirmed in both 
our partial-thickness and full-thickness wound porcine models.  All toxicology studies 
performed to date have shown no toxicity and no adverse events have been observed in 
multiple animal studies including a variety of animal species and several routes of drug 
administration. 
 
Significance:  
SynePure Wound Cleanser and Catasyn Advanced Technology Hydrogel demonstrates an 
improvement in healing, scarring, fibrosis, and infection of burn wounds and complex open 
wounds.  Its toxicity profile, ability to remove biofilms, healing, and anti-inflammatory 
properties make a compelling case for further testing of SynePure Wound Cleanser and 
Catasyn Advanced Technology Hydrogel as a new agent to facilitate healing and limit 
scarring in burn wounds. 
 
3.0 Research Design and Methods:  


 
            
                             
 
4
The study is a prospective, parallel group, randomized controlled trial comparing SynePure 
Wound Cleanser and Catasyn Advanced Technology Hydrogel (intervention group) to the 
current gold standard treatment Silvadene (control group). Subjects will be randomized 1:1, 
either to the treatment group or the standard of care (Silvadene) control group. 
Prior to the candidate’s referral into the study, as part of standard of care in the burn center, 
the burn wound is debrided and cleansed in the hydrotherapy area, and then assessed to 
categorize the burn (superficial, partial thickness,).   
 
 
Procedural Summary:  
1. After informed consent process is completed, the study investigator examines and 
screens the participant to confirm the diagnosis of a superficial-partial thickness burn and 
all other eligibility inclusion/exclusion criteria.  Medical history, medical record review with 
participant report, medication profile collections, vital signs, demographics, physical exam 
with burn wound and surface area assessments are completed at this time. Upon 
completion of these assessments’ all findings are reviewed and participant eligibility is 
determined based on study inclusion and exclusion criteria.  
 
2.  Should participant be deemed eligible to continue in research; randomization is 
performed to determine group assignment with randomization to either the intervention 
group (SynePure Wound Cleanser and Catasyn Advanced Technology Hydrogel) or the 
control group (Silvadene). Prior to application of treatment agent and dressing application, 
2D photographs will be taken of the burn area for later evaluation.   
 
3. During the Initial treatment visit (Day 0), after randomization, the treatment agent is 
applied (SynePure Wound Cleanser and Catasyn Advanced Technology Hydrogel or 
Silvadene) to complete secondary dressing with a dry gauze and Kerlix wrap application.   
 
4. Patient education on wound care and daily dressing change per routine care. Dressing 
to be changed daily by patient or provider. Education also provided as to the treatment 
agent to be applied daily with the dressing change (SynePure Wound Cleanser and 
Catasyn Advanced Technology Hydrogel or Silvadene).  
 
5. Participants will be asked to complete Subject report questionnaires related to the burn 
wound, symptoms experienced and effects of injury on their activities of daily living.   
 
6. The research coordinator will call the participant twice at timepoint Day 1 and Day 3 to 
assess participant safety, complications/adverse events and address any questions or 
concerns that the participant may have encountered.      
 
7. Follow-up Visits (Visits 2-8) will occur in the UPMC Mercy Burn Center and will consist of 
wound evaluation, brief history and physical assessment, vital signs, recording of status 
change since last visit/interaction, medication review, and adverse event collection. 2D 
photographs will be obtained of burn wound area at time of physical assessment and 
Subject report questionnaires and wound dressing assessment /treatment agent application 
(if wound has not yet healed). Reference to the Schedule of Events included with Protocol 
for additional detail of study procedures. 
 
Recruitment: 
Subjects presenting to the study site for treatment of superficial partial thickness burns will be 
considered for enrollment.  Physicians and licensed clinicians within the burn center area, familiar 
with the study’s inclusion/exclusion criteria will assess for potential patients as they arrive to the 


 
            
                             
 
5
Burn Center Clinic for treatment, a part of their burn practice.  If the patient is an appropriate 
candidate and willing to be considered for the study, he/she will be referred to the research team.  
 
After informed consent has been obtained, the study investigators will conduct screening 
procedures to determine study eligibility.  Should the participant meet criteria, he/she will proceed 
to randomization on Day 0 prior to treatment application. Enrolled subjects will be randomly 
assigned per a predefined 1:1 randomization scheme to either the interventional group or control 
group. 
 
 
Active Treatment: 
During the initial treatment visit (Day 0), the wound will undergo hydrotherapy debridement per 
routine care and at which time 2D photographs of the wounds will be obtained prior to 
randomization. Participants assigned to each group will have their treatment applied per their 
randomization status, either SynePure Wound Cleanser and Catasyn Advanced Technology 
Hydrogel (intervention group) or Silvadene (control group). They also will be given written 
instructions on how to apply the treatment at home and a sufficient supply to last until their next 
visit. 
 
Consent and Screening procedures:  
All screening procedures will be performed at the UPMC Mercy burn center in a private 
room after this informed consent document is signed. These screening procedures will take 
approximately 2-3 hours. 
 
• Informed consent 
• Review of medical records related to the injury, past surgeries, and general health 
events 
• Demographic information and allergy collection 
• Physical assessment inclusive of an evaluation to your burn wound area  
• Medication collection 
• Vital sign measurement (such as temperature, heart rate, blood pressure and respiration 
rate) collection 
• Pregnancy Test (Urine Dip) 
 
Initial Treatment Visit 1 (Day 0): 
After all screening procedures have been completed and reviewed by the investigators and 
eligibility will be determined.  Should the participant be determined to be eligible to continue 
participation, the initial treatment procedures will be continued and all procedures may 
occur on the same day as the screening visit. This visit will be performed at the UPMC 
Mercy Burn Center. The total length of time for this visit will take approximately 2-3 hours of 
time. 
 
• Randomization process with assignment to 1 of 2 treatment groups where either 
SynePure Wound Cleanser with Catasyn Advanced Technology Wound Hydrogel OR 
Silvadene will be applied.  Both groups will then receive a secondary dry dressing 
covering consisting of gauze and Kerlix wrap.  
• 2D photographs will be obtained focusing on the burn injury area, prior to the wound 
being dressed. 
• Written instructions will be provided describing how to apply the wound treatment and 
dressings daily in between to the participant.  Should the participant be in hospital 
during the healing of the burn wound these daily dressings will be performed by either a 
member of the clinical staff or the research team.   


 
            
                             
 
6
• Completion of Subject Self-report questionnaires that pertain to the burn wound, pain, 
and other symptoms that experience.  Potential effects and relationship to the 
participant’s quality of life and activities of daily living 
• Adverse events collection  
 
After this initial visit, the research team will reach out to the participant by phone on Day 1 
and Day 3 of the study schema to determine if there are any questions, issues or concerns 
that the participant may be experiencing. Additionally, they will remind and confirm the next 
in person visit to the clinic. 
 
Follow-up Visits (Visits 2-8): 
These Visits will occur in the UPMC Mercy Burn Center and have a duration of 1-2 hours to 
complete.  These visits will consist of wound evaluation to assess for healing, brief history 
and physical assessment, vital signs, recording of status change since last visit/interaction, 
medication review, and adverse event collection. 2D photographs will be obtained of burn 
wound area at time of physical assessment and prior to wound dressing /treatment agent 
application (if wound has not yet healed) and subject report questionnaires consisting of 
SF-12, Wound Experience and Satisfaction questionnaires, Vancouver Scar Scale, POSAS 
Questionnaires (described in the following section). During the study visit, continued 
instructions for at home dressing and treatment application will be reinforced.  
 
Subject Reported Questionnaires: 
Vancouver Scar Scale Score: The VSS9 is a scale to assess the extent of scarring for a given 
wound by scoring the pigmentation, vascularity, pliability and height of the scar. Each domain is 
individually scored then the domains are summed to give a total score that range from zero (0) to 
13 with zero (0) representing a ‘normal’ presentation. Validity and reliability of the scale have 
been documented10-12 and is commonly used in wound healing research.  
 
SF-12: The SF-1213, an abbreviated version of the SF-36, is a patient self-reported twelve 
questions survey of general health, physical functioning, role functioning (physical and 
emotional), bodily pain, vitality, mental health, and social functioning. The scale is 
comprised of two scores: physical component summary (PCS) and mental component 
summary (MCS).  Scores are summarized and normalized. While the survey demonstrates 
moderate validity and reliability,14 the survey is ideal for use as it is brief and commonly 
used, so comparisons between studies are possible. 
 
POSAS: The patient and observer scar assessment scale15-16 is used to measure scar 
quality. It is composed of a patient reported section and an observer reported section. Each 
section consists of six items that are scored numerically on a ten-step scale. These are 
then summed together to make up the total score. There is also an overall opinion section 
for both the patient and the observer. While validity and reliability are marginal for the 
POSAS, scores have shown little variance from the gold standard, the Vancouver Scar 
Scale, and it has the distinct advantage of incorporating the patient’s perspective.  
 
Wound Experience Questionnaire: The wound experience questionnaire17 consists of 
three sections regarding the patient’s wound. The questionnaire is used for wounds early 
into the healing process and wounds that have dressings. This has been primary used in 
patients with surgical wounds but can be adapted to wounds not specifically operative, such 
as burns. Validity and reliability evidence have not been published but the questionnaire 
has the unique capability to assess a primary focus of this study. In addition to assessing 
patient satisfaction with the healing process, the questionnaire also assesses patient 
satisfaction with the wound dressings as distinct categories.  


 
            
                             
 
7
 
3.1 Data Collection and Statistical Consideration: 
Sample Size Estimation: 
In this study, the minimal median difference of three (3) days to healing is determined to be 
the clinically relevant difference. Given an assumed median time of 15 days to healing for 
the Silvadene comparator group18, a corresponding hazard ratio of 0.8 for the intervention 
group is anticipated. a sample of 45 in each group (90 total) is required to detect a 
statistically significant difference [confidence level (α ≤ 0.05) – 95%; Power – 80%]. 
Assuming a 10% attrition, it is recommended to enroll up to 100 subjects to achieve a 
sample of 90 subjects. This will be easily accomplished in our outpatient burn clinic, with a 
400-patient annual volume, and we will use a 3-week evaluation period so that the trial can 
be accomplished in a year.  
 
Analytic Plan: 
Descriptive statistics will be presented as means and standard deviations for continuous 
data and as counts and percentages for dichotomous and categorical data. Time-to-event 
curves with Kaplan-Meier (KM) estimates will be used to compare overall median time to 
wound healing between treatment groups. Comparison of KM curves will be performed 
using the log rank test as the curve is assumed to be non-parametric or semi-parametric, 
and the baseline hazard is not related to the group assignment. Relevant clinical and 
demographic variables may be assessed for their independent contribution in time-to-event 
outcome using univariate screening and the hazard is assumed to be relatively constant 
across the study window. Multiple regression modeling (Cox Proportional Modeling) and 
adjusted KM curves will be assessed as appropriate. Variables will be included in the 
multivariate analysis if the univariate screening p-value is < 0.10 and multivariate 
parameters will be presented as hazard ratios with their corresponding 95% confidence 
intervals.  
 
Infection, complication, and progression rates will be compared using the Chi-squared test 
or the Fisher exact test if the data is very unequally distributed within the contingency table, 
which is anticipated for infection rates. Repeated Measure Analysis of Variance (ANOVAs) 
will be performed to assess differences in PROs with the days since wounding as the 
Within-Subjects factor and treatment groups as the Between-Subjects factors. Bonferroni 
post-hoc analyses may be performed for all statistically significant main effects. Baseline 
demographic and clinical characteristics will be compared between treatment groups with 
Independent samples t-test for continuous data and Chi-squared test for dichotomous and 
categorical data. 
 
Analysis will be performed using SPSS (IBM SPSS Statistics for Windows, Version 25.0. 
Armonk, NY: IBM Corp.) and statistical significance will be determined at p ≤ 0.05 with the 
exception of univariate screening as previously described. 
 
 
Outcome definitions: 
1. Healed wound: 90% reepithelialization (skin and mucous membrane replacement) of 
the wounded area. 
2. Infection: characterized by local new inflammation, heat, purulence as well as new or 
increased pain, redness and swelling 
3. Complications other than infection: gangrene, necrosis, periwound dermatisis and/or 
edema, hematoma, or any other complication determined to be related to the wound 
and/or treatment 


 
            
                             
 
8
4. Progression; recategorization of the wound to a more advanced state deep partial 
thickness, full thickness. Failure to heal with 21 days of injury also may be 
determined as progression by the investigator.  
 
4.0 Human Subjects: 
4.1 General Characteristics: 
Inclusion criteria: 
• 18 years of age or older, Male and Female 
• Ability to provide informed consent 
• Patients who have sustained superficial, partial thickness burn wounds ≤ to10% of total 
body surface area (TBSA) 
• Patients otherwise in good general physical and mental health, as per the 
investigator’s clinical judgment 
 
Exclusion criteria: 
• Inability to provide informed consent 
• Deep partial-thickness burns and full-thickness burns    
• Radiation, chemical or electrical burn injury  
• Patients with burns primarily located to the face, genitals, or span across joints 
• Patients whose burn injury was ≥ to 48 hours prior to entry into the UPMC Mercy Burn 
Clinic.   
• Patients with uncontrolled cerebrovascular disease, cardiovascular disease, 
concurrent endocrine, hepatic or renal disease, or other severe conditions for whom, in 
the investigators’ discretion would render study participation unsafe  
• Current pregnancy 
• Patients with concurrent burn related injuries or inhalation injury that would put the 
patient at increased risk, per physician discretion 
• Any condition to which in the investigator’s discretion would render study enrollment a 
safety concern for the patient. 
All patients who present to the UPMC Mercy ER or Burn Center, whose burns are assessed 
to be superficial, partial thickness burns, and who also meet the study’s eligibility criteria in 
the opinion of the referring physician will be considered for participation. 
 
The racial, gender and ethnic characteristics of the proposed subject population reflects the 
demographics of Pittsburgh and the surrounding area and/or the patient population of the 
University of Pittsburgh Medical Center. We shall attempt to recruit subjects in respective 
proportion to these demographics. No exclusion criteria shall be based on race, ethnicity, 
gender, or HIV status. 
 
The study will plan to enroll 115 subjects in order to randomize 100 subjects, to either the 
intervention group (SynePure Wound Cleanser and Catasyn Advanced Technology 
Hydrogel) or the control group (Silvadene).  It is expected that some subjects will not meet 
screening criteria after they are consented, and will therefore not proceed forward to 
randomization. 
 
4.4 Recruitment Procedures: 
Subjects presenting at the UPMC Mercy burn center (whether initially seen at the Mercy 
Emergency Center, or at the outpatient burn clinic) for the treatment of burn wounds will be 
considered for enrollment.  The potential candidate while in the hydrotherapy area, where 


 
            
                             
 
9
as standard of care, the burn wounds are debrided and assessed for depth classification 
will be introduced to the study.  Appropriate candidates will be introduced by the treating 
physicians and clinical team to the research and will determine interest from the potential 
candidate in the research. If interest is expressed, the potential candidate will be introduced 
to the study team and the informed consent process will be initiated, should the candidate 
express willingness to proceed. Informed consent will be performed prior to any screening 
or intervention procedures. 
 
The study investigator along with the research coordinator will discuss with the subject the 
nature of the research study, design schema, the risks and benefits, cost and payments 
and rights as a research subject participant. The potential subject will be provided with 
ample time to review the informed consent document and ask questions. Should the 
potential subject wish to take additional time to review the consent or discuss it with his/her 
family, or medical personnel he/she will be able to.  The study investigator will provide the 
potential subject a private area within the burn center to conduct this informed consent 
document review prior to signing the informed consent. 
 
Technical terms will be described using lay terminology and subjects will be permitted and 
encouraged to ask questions, and all will be answered to their satisfaction.  In addition to 
the consent, the study schema lists the elements of each visit’s requirements for 
participation in a visual and accessible way.  Study investigators, or their clinical designee, 
will be responsible for obtaining informed consent and signing the informed consent 
document. 
4.5 Risk/ Benefit Ratio: 
 
As part of this study’s goals are assessing the safety of the intervention treatment in patients 
with superficial partial-thickness burns, not all possible risks and adverse effects are known.  
 
Risks associated with SynePure Wound Cleanser and Catasyn Advanced Technology 
Hydrogel include: 
SynePure Wound Cleanser 
Has been approved for external use in cleaning dermal wounds (including superficial 
partial-thickness burn wounds). 
• There were no adverse events found upon topical application. 
 
Catasyn Advanced Technology Hydrogel 
Has also been approved for external use for dressing of wounds (including superficial 
and superficial partial-thickness burn wounds). 
• There is a low risk of redness where the hydrogel is placed on the skin. 
 
Risks associated with Silvadene include: 
• Dermatologic 
o Skin discoloration  
o Burning sensation 
o Itching  
o Rashes  
o Skin photosensitivity (sensitivity to sunlight) 
o Skin necrosis (death of skin) 
• Gastrointestinal reactions/ upset stomach  


 
            
                             
 
10
• Renal 
o Interstitial nephritis (inflamed kidneys) 
• Hepatic  
o Hepatitis (inflamed liver) 
Uncommon risks associated with Silvadene include: 
• A small risk of adverse reaction associated with systemic absorption (This may lead 
to deposition of silver in your organs. 
• Blood disorders   
o Agranulocytosis- dangerously low level of white blood cells, leading to 
immunocompromise  
o Aplastic anemia- body stops producing enough new blood cells  
o Thrombocytopenia- decreased platelet count  
o Leukopenia- decreased neutrophil count  
o Hemolytic anemia- destruction of red blood cells faster than they are produced  
• Dermatologic and allergic reactions 
o Stevens-Johnson syndrome (SJS) 
o Toxic epidermal lysis (TEN) 
o Exfoliative dermatitis 
• Hepatocellular necrosis 
• CNS reactions 
• Toxic nephrosis 
 
Additional risks associated with the study protocol include: 
• A breach of confidentiality. 
• Distress or anxiety associated with completing the questionnaires  
There is no known direct benefit to the study participants.  There may be direct benefit due to 
an additional period of monitoring and therapy beyond typical standard of care. While there is 
no guarantee or benefit from this research, demonstrating safety and preliminary efficacy of 
these devices could provide a new approach in partial thickness burn treatment and could 
prevent decreased function and disability in civilian and military trauma.  
 
5.0 Costs and Payments: 
Costs: The study treatments (SynePure and Catasyn, and Silvadine) and will be provided 
by the manufacturer for this study, and research procedures will be completed at no cost to 
the participants.  However, all standard of care procedures (i.e. recommended labs or 
scans) and costs associated with burn treatment visits will be charged to the participant’s 
insurance, and they will be responsible for all associated test or visit co-pays as well.  
 
Reimbursement: Participants may receive a parking voucher for the research visits (visits 
3,4,6,7) should the actual visit exceed 2 hours in duration. Participants may also be 
reimbursed up to a total of $40.00 ($10.00 gift card for each completed research visit 
3,4,6,7).  
 
6.0 Appendices: 
See attached informed consent form, schema table and subject dressing instruction, 510K clearance 
product files and package insert.  
 
6.1 Qualifications of Investigators: 
 
 


 
            
                             
 
11
J. Peter Rubin, MD, Founding Chair of the Department of Plastic Surgery at the University of 
Pittsburgh. Dr. Rubin has a successful track record of implementing Department of Defense clinical 
trials under programs including the Biomedical Translational Initiative, the Armed Forces Institute of 
Regenerative Medicine, and the Office of Technology Transfer Clinical Trials Program. He is an 
internationally recognized board-certified plastic and reconstructive surgeon, as well as a scientific 
researcher with an active basic science laboratory (Co-Director of the Adipose Stem Cell Center) 
who holds funding from the National Institutes of Health. As Principal Investigator, Dr. Rubin will 
provide medical oversight for study subjects, study eligibility determination, the consenting process, 
research study procedures, overall protection of human subject risks and benefits, and performance 
of clinical trial conduct and compliance under Good Clinical Practice (GCP) standards. 
 
Jenny Ziembicki, MD Medical Director, UPMC Mercy Burn Center: Dr. Ziembicki has a special 
interest in the development of UPMC Mercy’s comprehensive outpatient burn therapy program, 
which allows patients a more expedient return to a productive lifestyle. As a co-investigator on this 
project she will provide clinical oversight for study subjects, will be responsible for collection of 
information assessing the research study eligibility criteria, the consenting process, research study 
procedures, overall protection of human subject risks and benefits, and performance of clinical trial 
conduct and compliance maintaining GCP standards.  In addition, with the other burn center 
physician co-investigators, she will confirm the determination of ≥ 90% re-epithelization and time to 
heal for the participants’ burn wounds. 
 
Alain Corcos, MD, Division Chief & Trauma Medical Director, UPMC Mercy: Dr. Corcos is a board-
certified surgeon whose research interests include wound dressing effects, and autologous 
noncultured cell-spray grafting in the treatment of burns. As a co-investigator on this project, with 
the other burn center physician co-investigators, he will confirm the determination of ≥ 90% re-
epithelization and time to heal for the participants’ burn wounds. 
 
Garth Elias, MD, Clinical Associate Professor of Surgery: As a co-investigator on this project, Dr. 
Elias will assist Drs. Ziembicki and Corcos.  With the other burn center physician co-investigators, he 
will confirm the determination of ≥ 90% re-epithelization and time to heal for the participants’ burn 
wounds. 
 
Francesco Egro, MD Resident, Department of Plastic Surgery at the University of Pittsburgh 
Dr. Egro pursued his Bachelors of Science with Honors in Microbiology and his Medical Degree from 
the University of Bristol, United Kingdom. He then served as a research fellow at the Division of 
Plastic Surgery at Emory University under the mentorship of Dr. Albert Losken, where he conducted 
his research on breast oncoplastic surgery.  Dr. Egro is currently a member of the American Society 
of Plastic Surgery, Royal College of Surgeons of England, and the American Burn Association, 
where he also serves on their Education Committee.  Dr. Egro’s clinical and research interests 
include microsurgery, burns, surgical education, and adipose-derived stem cells.  Dr. Egro will serve 
as a co-investigator and assist the PI with medical oversight for study subjects, study eligibility 
determination, the consenting process, and research study procedures. In addition, he will assist with 
data analysis, manuscript writing and publication of results, and will serve to compile analysis of the 
burn wound photographs. 
 
Patsy Simon, BS, RN, CCRC, CCRA, ACRP-PM Director, Regulatory and Clinical Affairs for the 
UPMC Center for Innovation in Restorative Medicine, Department of Plastic Surgery at the University 
of Pittsburgh: Ms. Simon has over 34 years of clinical nursing experience with over 20 years of 
expertise in clinical research trial conduct and compliance. She has regulatory expertise in federal, 
industry and investigator initiated clinical trials, with strong experience in federal IND and IDE 
application development and management. Ms. Simon’s role on this project as a co-investigator will 
be in the development stage and concentration of research procedural feasibility, regulatory and 


 
            
                             
 
12
clinical management and clinical staff operations. She will oversee the development of compliance 
standards, quality management process as they pertain to the research execution and adherence to 
federal, state and local regulations, and ICH Good Clinical Practice (GCP) guidance during the 
conduct of the project. 
 
Rebecca Parsons, PA-C Department of Plastic Surgery at the University of Pittsburgh: Ms. Parsons 
has 3 years of experience as a surgical physician assistant prior to her role in research. Before 
working in plastic surgery, she was employed by an orthopedic surgery group where she worked for 
three years as a first assist in a variety of orthopedic cases, including trauma care. She is also 
trained in both inpatient and outpatient perioperative care settings. Before obtaining her Master’s 
Degree as a Physician Assistant, she graduated with a Bachelor’s degree in Biochemistry from 
Grove City College. Her role on the study as a co-investigator will include assisting the physician 
investigators with screening and enrollment, administration of the study treatments, and follow up 
visit procedure completion. 
 
Eleanor Shirley, M.A. Department of Plastic Surgery at the University of Pittsburgh: Ms. Shirley has 
20 years of experience at the University of Pittsburgh as a senior research study coordinator, 
focused on surgical outcomes, mental health/quality of life and diabetes. She has experience in 
screening participants and recruitment, conducting certified assessments, data review/management 
and regulatory requirements. She has participated in grant writing and submission, and is cognizant 
of study fiscal issues, both pre- and post- award. Post data collection, she has served as a member 
on writing group committees and been a submitting author of study results for publication. Her role in 
the study as a research coordinator will include research training activities, quality management, 
regulatory compliance, oversight of recruitment after initial referral, screening and enrollment, study 
visits completion, data collection, analysis and transfer, and participant retention. 
 
Shawna Reekie, Department of Plastic Surgery at the University of Pittsburgh: Ms. Reekie will serve 
as the primary coordinator for this clinical trial.  Her role as a research coordinator will be to assist 
with recruiting patients, completing study visits, data collection, protocol adherence, patient retention, 
and submission of regulatory documents. 
 
Alexandra McCloskey, MS, Department of Plastic Surgery at the University of Pittsburgh.  
Ms. McCloskey has several years of experience as a research coordinator in multiple different 
disciplines. She has experience in screening patients and recruitment as well as maintaining 
regulatory documents and completing start-up processes. Her role as a research coordinator will 
be to assist with recruiting patients, completing study visits, data collection, protocol adherence, 
patient retention, and submission of regulatory documents. 
 
6.2 References: 
 
 
1. Church, D.; Elsayed, S.; Reid, O.; Winston, B.; Lindsay, R. Burn wound infections. Clin. 
Microbiol. Rev. 2006, 19, 403–434.  
2. Duran N, Duran M, de Jesus MB, Seabra AB, Favaro WJ, Nakazato G. Silver nanoparticles: a 
new view on mechanistic aspects on antimicrobial activity. Nanomedicine 2016;12:789–799. 
 
3. Aziz Z, Abu SF, Chong NJ. A systematic review of silver-containing dressings and topical 
silver agents (used with dressings) for burn wounds. Burns 2012;38:307–18. 
4. Aurora A, Beasy A, Rizzo JA, Chung KK. The use of a silver-nylon dressing during evacuation 
of military burn casualties. J Burn Care Res 2018; 39:593–597. 
5. Barajas-Nava LA, Lopez-Alcalde J, Roque I Figuls M, Sola I, Bonfill Cosp X. Antibiotic 
prophylaxis for preventing burn wound infection. Cochrane Database Syst Rev 2013;6: 
CD008738. 
6. Wasiak J, Cleland H. Burns: dressings. BMJ Clin Evid. 2015; 2015: 1903. 


 
            
                             
 
13
7. Narayanaswamy VP, Giatpaiboon SA, Uhrig J, et al. In Vitro activity of novel glycopolymer 
against clinical isolates of multidrug-resistant Staphylococcus aureus. PLoS One. 
2018;13(1):e0191522. Published 2018 Jan 17. doi:10.1371/journal.pone.0191522. 
8. Narayanaswamy VP, Keagy LL, Duris K, et al. Novel Glycopolymer Eradicates Antibiotic- and 
CCCP-Induced Persister Cells in Pseudomonas aeruginosa. Front Microbiol. 2018;9:1724. 
Published 2018 Aug 3. doi:10.3389/fmicb.2018.01724. 
9. Sullivan T, Smith J, Kermode J, Mclver E, Courtemanche DJ. Rating the Burn Scar. J Burn 
Care Rehabil. 1990;11:256–260. 
10. Oliveira GV, Chinkes D, Mitchell C, Oliveras G, Hawkins HK, Herndon DN. Objective 
assessment of burn scar vascularity, erythema, pliability, thickness, and planimetry. Dermatol 
Surg. 2005;31:48–58. 
11. Li-Tsang CWP, Lau JCM, Liu SKY. Validation of an objective scar pigmentation 
measurement by using a spectrocolorimeter. Burns. 2003;29:779–784. 
12. Baryza MJ, Baryza GA. The Vancouver Scar Scale: an administration tool and its interrater 
reliability. J Burn Care Rehabil. 1995;16:535–538. 
13. Maruish M. User’s manual for the SF-12v2 Health Survey. 3. Lincoln, RI: QualityMetric Inc.; 
2012. 
14. Cheak-Zamora NC, Wyrwich KW, McBride TD. Reliability and validity of the SF-12v2 in the 
medical expenditure panel survey. Qual Life Res. 2009 Aug;18(6):727-35. 
15. Draaijers, LJ, Tempelman, FR, Botman, YA, Tuinebreijer, WE, Middelkoop, E, Kreis, RW, et 
al. The patient and observer scar assessment scale: a reliable and feasible tool for scar 
evaluation. Plast Reconstr Surg. 2004;113:1960-1965. 
16. Van de Kar, AL, Corion, LU, Smeulders, MJ, Draaijers, LJ, van der Horst, CM, van Zuijlen, 
PP. Reliable and feasible evaluation of linear scars by the Patient and Observer Scar 
Assessment Scale. Plast Reconstr Surg. 2005;116:514-522. 
17. Elliott D; Bluebelle Study Group. Developing outcome measures assessing wound 
management and patient experience: a mixed methods study. BMJ Open. 2017;7(11):e016155.  
18. Nherera L, Trueman P, Roberts C, Berg L. Silver delivery approaches in the management of 
partial thickness burns: A systematic review and indirect treatment comparison. Wound Repair 
Regen. 2017 Aug;25(4):707-721. 


 
            
                             
 
14
 
 
 
NCT number: 
NCT04601532 
 
Official Title: Randomized Controlled Trial Assessing a Novel Glycopolymer Compound in 
the Treatment of Superficial Partial-Thickness Burns 
 
Study Consent Document Date: IRB Approved 12/20/2022 
 
 
 


 
            
                             
 
15
  
UNIVERSITY of PITTSBURGH  
                                                                         
Department of Plastic Surgery  
CONSENT TO ACT AS A PARTICIPANT IN A RESEARCH STUDY 
TITLE: “Randomized Controlled Trial Assessing a Novel Glycopolymer Compound in 
the Treatment of Superficial Partial-Thickness Burns” 
KEY INFORMATION 
You are being asked to take part in a research study.  Research studies include only people 
who choose to take part.  The study team members will explain the study to you and will 
answer any questions you might have.  You should take your time to make your decision. 
• The purpose of this study is to compare the safety and effectiveness of SynePure™ 
Wound Cleanser and Catasyn™ Advanced Technology Wound Hydrogel against the 
standard of care therapy (Silvadene) for superficial partial-thickness burns.   
• Superficial partial-thickness skin burns, previously called second-degree burns, 
involve the top two layers of skin, are painful with air movement or air temperature 
changes, are red and seep fluid, usually form blisters, and turn white when pressed. 
Superficial partial- thickness skin burns heal within seven to 21 days. The burned 
area may permanently become darker or lighter in color but a scar does not usually 
form. Sunburns that blister after several hours are good examples of superficial 
partial-thickness burns.Your study participation will last up toa maximum of 21 days 
and consist of up to a maximum of eight in-person visits.  
• There will be 115 subjects enrolled into this study to enable 100 subjects to undergo 
the randomization assignment procedure 
• Subjects will be male and female,18 years of age and older, with a diagnosis of 
superficial partial-thickness burn injury.  
• The study will involve the application of either SynePure Wound Cleanser and 
Catasyn Advanced Technology Wound Hydrogel or the standard of care therapy 
(Silvadene), for treatment of your burn. Prior to treatment application, we will obtain 
2D photographs and ask you to complete questionnaires pertaining to your burn 
symptoms, treatment satisfaction and quality of life. 
• Risks include reactions to either of the study treatments, discomfort related to the 
questions being asked of you, and the potential of breaches in confidentiality of your 
personal information. 
• You may or may not personally benefit from your participation in this study. You may 
experience improvement in burn wound healing, and/or a potential for reduction of 
infection rates; however, there is no guarantee that you will receive such a benefit. 
This study may help us to understand how SynePure Wound Cleanser and Catasyn 
Advanced Technology Wound Hydrogel compares to the standard of care 
(Silvadene) in terms of safety and effectiveness. 


 
            
                             
 
16
• If you decide not to participate in this experimental study, there are several other 
treatments or procedures, some of which you may wish to consider are below: 
o Participating in another study 
o Standard of care treatment 
PRINCIPAL INVESTIGATOR:  
Dr. J. Peter Rubin, M.D., 
UPMC Endowed Professor and Chair of Plastic Surgery 
Professor of Bioengineering, University of Pittsburgh 
UPMC Center for Innovation in Restorative Medicine 
3380 Blvd. of the Allies, Suite 158 
Pittsburgh, PA 15213 
412-383-8080 
24-hour contact number- 412.647.2345 
CO-INVESTIGATORS: 
Jenny Ziembicki, MD                                          UPMC Mercy (UPMC Mercy Burn Center) 
Medical Director, Burn Center, UPMC Mercy                                          
Alain Corcos, MD                                                                        Division of General Surgery 
Garth Elias, MD                                                                      1400 Locust Street, Suite 4214 
Francesco Egro, MD                                                                           University of Pittsburgh 
Patsy Simon, BS, RN, CCRC, CCRA, ACRP-PM                   Department of Plastic Surgery 
Rebecca Parsons, PA-C                                                                         Scaife Hall, Suite 6B  
Elena Nikonova, MD                                                                                 3550 Terrace Street 
Guy Stofman, MD, FACS                                                                       Pittsburgh, PA 15261 
Clinical Research Coordinator(s):  
412-641-8676 
Anne Lindsey, BS 
lindseyal2@upmc.edu 
Eleanor Shirley, MA, CCRC 
shirleye@upmc.edu 
Giuliana Latella, BS, MS 
latellagm3@upmc.edu 
Sources of Support: Department of Defense 
Why is this research being done?  
This research study will assess the safety and effectiveness of SynePure Wound Cleanser 
when used with Catasyn Advanced Technology Wound Hydrogel compared to the standard 
of care treatment (Silvadene) in superficial partial-thickness burns.  


 
            
                             
 
17
SynePure Wound Cleanser is being used under its FDA 510K clearance for its intended use 
and indication.  Although Catasyn Advanced Technology Wound Hydrogel has FDA 510K 
clearance, for this study, it is being used under an abbreviated investigational device 
exemption submission, as a nonsignificant risk device and as an FDA regulated product.  An 
investigational device exemption (IDE) allows the investigational device to be used in a 
clinical study in order to collect safety and effectiveness data.   Studies of non-significant 
risk devices are subject to abbreviated IDE requirements. An IDE submission to the FDA is 
not required under the abbreviated requirements, but the requirements for labeling, IRB 
approval, informed consent, monitoring, records, reports and promotional practices 
contained in FDA regulations still apply (21 CFR 812.2(b)). 
The primary purpose of this study is to assess the time to heal, or the number of days that it 
will take for your burn wound to heal when treated with either the intervention or the 
standard of care dressing. We will define for the purpose of this study, healing as ≥ 90% 
closure of the burn surface area.  
The secondary purpose of this study is to examine the outcome of your healed burn wound. 
The characteristics to be reviewed include  how easy the wound is to move, its color, skin 
pigmentation, and whether or not you develop a scar. You will be asked to describe your 
wound, in terms of pain, itching, dryness, and irritation, and also, to rate your wound on the 
impact it has on your daily living.   
This study is designed with a randomized controlled procedure to assign your treatment 
group, meaning like a flip of a coin, you would have a 50% chance of receiving the study 
intervention treatment or a 50% chance of receiving the standard of care treatment. You will 
be aware of which group you are randomized into. We plan to consent up to 115 participants 
to enable 100 of these participants to be randomized into two-groups; 50 to the 
interventional group and 50 to the standard of care group. 
How long will I be in this research?  
We are looking to enroll male and female participants to this study, 18 years of age or older 
who have received a superficial partial-thickness burn. Your study participation may last up 
to a total of 21 days. The number of visits that you have will vary, and will be determined on 
your wound’s individual healing time. If your wound does not heal by visit 8, the last 
planned study visit, you will end your study participation. However, your clinical care will 
continue with your burn physician at the UPMC Mercy burn center, and you will continue to 
receive standard of care treatment for your burn. 
What treatments or procedures are available if you decide not to take part in this 
research study? 
If you decide not to participate in this experimental study, there are other treatments or 
procedures you may wish to consider: 
• Participating in another study 
• Standard of care treatment for your burns 
What procedures will be performed for research purposes? 


 
            
                             
 
18
If you decide to participate in this study, we will do some or all of the following tests to see 
if you are eligible for the study. The following procedures will be completed after you have 
discussed the study with your physician and signed the informed consent.  
Consent and Screening Procedures:  
All screening procedures will be performed at the UPMC Mercy Burn Center in a private 
room after this informed consent document is signed. These screening procedures will take 
approximately 2-3 hours. 
• Informed consent 
• Review of medical records related to your injury, past surgeries, and general health 
events 
• Demographic information and allergy collection 
• Physical assessment inclusive of an evaluation to your burn wound area  
• Medication collection 
• Vital sign measurement (such as temperature, heart rate, blood pressure, and 
respiration rate) collection 
• Pregnancy test (urine dip) 
Initial Treatment Visit 1 (Day 0): 
After all screening procedures have been completed and reviewed by the 
investigators,eligibility will be determined.  If you are found to be eligible, you may 
continue to the initial treatment procedures, and they may occur on the same day as the 
screening visit. This visit will also be performed at the UPMC Mercy Burn Center. The total 
length of time for this visit will take approximately 2-3 hours of additional time. 
• Randomization process with assignment to 1 of 2 treatment groups, where either 
SynePure Wound Cleanser with Catasyn Advanced Technology Wound Hydrogel 
OR Silvadene will be applied.   
• Both groups will then receive a secondary dry dressing covering, consisting of gauze 
and Kerlix wrap.  
• 2D photographs will be obtained focusing on the burn injury area, prior to the wound 
being dressed. 
• Written instructions will be provided describing how to apply the wound treatment 
and dressings daily in between your clinic visits. If you are randomized to the 
intervention group, you will be asked to remove your old dressing on a daily basis, 
and gently cleanse your wound with SynePure™ Wound Cleanser to remove all 
remaining product ointment from your skin (using up to 125 ml or the entire bottle 
provided). Then you will be asked to allow your wound to air dry for 1 minute. 
Afterwards, you will apply Catasyn™ Advanced Technology Hydrogel onto your 
wound (can use 2 ml twice daily, or up to 4 ml total which is a little less than a 
teaspoon). Finally, you will redress your wound, with the supplies provided to you 
by the study team. Should your dressing become dislodged, you will be asked to 
repeat the steps listed above.  Should you be admitted to the hospital during the 
healing of your burn wound, these daily dressings will be performed by either a 
member of the clinical staff or the research team.  


 
            
                             
 
19
• You will be asked to complete a few questionnaires that pertain to your burn wound, 
pain, and other symptoms that you may experience, and finally, the potential effects 
that this injury has on your quality of life and activities of daily living. 
• Adverse events collection  
After your initial visit, the research team will reach out to you by phone within 
approximately 24 and 72 hrs of your initial visit, to determine if there are any questions, 
issues or concerns that you may have. Additionally, they will remind and confirm with you 
the next in person visit to the clinic. 
Follow-up Visits (Visits 2-8):  
Some of these follow-up visits will be conducted  along with your weekly standard of care 
clinical visits (visits 2, 5 and 8), and some of these visits (visits 3, 4, 6, and 7) will be 
specifically for the purpose of this research study. These additional research visits will not 
be part of your clinical care and will not be billed to your insurance, nor will you incur a cost 
for any procedure performed. These visits may occur at either the UPMC Mercy Burn 
Center or the UPMC Aesthetic Plastic Surgery Center. The total length of time for each of 
these individual visits will be approximately 1-2 hours. Should you be unable to attend the 
research only visits (3, 4, 6, and 7) in person, you will be offered the option to complete 
them through telemedicine (a secure video call).  
These visits will consist of a burn wound evaluation to assess for healing, brief history and 
physical assessment, vital signs, recording of status change since last visit/interaction, 
medication review, and adverse event collection as listed below: 
• Vital signs (temperature, heart rate, respirations, blood pressure) collection  
• Review of your medications 
• Brief medical history, physical assessment, and assessment of your burn injury to 
determine healing 
• 2D photographs will be taken of the injured area 
• Treatment agent and secondary dry dressing- (for these procedures, you will be 
instructed to bring treatment and dressings to the clinic for the dressing change)   
• Adverse event collection 
• Questionnaires related to topics such as your burn wound symptoms, pain, and other 
symptoms that you may experience and finally the potential effects that this injury 
has on your quality of life and activities of daily living. 
What are the possible risks, side effects, and discomforts of this research study?  
As with any research or clinical procedure, there may be side effects that are currently 
unknown, and these unknown risks could be permanent, severe, life threatening, or may 
even cause death. You will be carefully observed and questioned pertaining to any side 
effects that you may be encountering. You should inform your study doctor about any side 
effects that you experience while taking part in the study. 
As part of this study’s goals are assessing the safety of the intervention treatment in patients 
with superficial partial-thickness burns like yours, not all possible risks and adverse effects 
are known.  


 
            
                             
 
20
SynePure Wound Cleanser 
Has been approved for external use in cleaning dermal wounds (including superficial 
partialthickness burn wounds). 
• There were no adverse events found upon topical application. 
• There is a risk of adverse reaction if you have an allergy to shellfish 
Catasyn Advanced Technology Hydrogel 
Has also been approved for external use for dressing of wounds (including superficial and 
superficial partial-thickness burn wounds). 
• There is a low risk of redness where the hydrogel is placed on the skin. 
• There is a risk of adverse reaction if you have an allergy to shellfish 
Silvadene 
• Skin reactions are the most common adverse reactions. Skin reactions include: skin 
discoloration, burning sensation, itching, rashes, skin photosensitivity – sensitivity to 
sunlight, and skin necrosis – death of skin. 
• Other less common advere reactions include: gastrointestinal reactions/upset stomach, 
inflamed kidneys, or inflamed liver. 
• Rare risks are associated with systemic absorption, and may lead to deposition of 
silver in your organs. 
▪ Blood disorders (a possibility of lower white cells, red cells or 
platelets) 
▪ Erosive skin reactions (this could lead to blistering of your skin and 
more severe effects such as hospitalization and in rare cases, even 
death) 
▪ Liver failure, as a result of silver deposits in your liver 
▪ Rarely, effects on your brain/spinal cord, such as long terms nerve 
symptoms related to balance and spatial perception 
▪ Kidney failure, as a result of silver deposits in your kidney 
Breach of Confidentiality 
• Participation in this research study does involve the potential risk of a breach of 
confidentiality of your medical record information, photography, and associated 
privacy of the participants.  
• Steps to minimize these risks include the following:  
o Removing direct patient identifiers (i.e. names, social security numbers, 
medical record numbers) from information stored in the study records 
o Securing, in a separate location, and limiting access to information linking 
subject ID numbers assigned to the study record information with direct 
patient identifiers 
• Limiting access to information contained within the study records to study 
investigators/research team only. 
Questionnaires 
• Infrequently, questions encountered during research visits may be distressing or 
anxiety provoking due to their personal or sensitive nature. You will not be required 
to answer any questions that are particularly distressing to you. 


 
            
                             
 
21
Reproductive Risks 
• Taking part in this study may result in unknown risks to an unborn baby, so you 
should not become pregnant while on this study. A urine pregnancy test will be 
completed during the screening portion of this study and if it is shown that you are 
pregnant, you will be excluded from participating.  
What are the possible benefits from taking part in this research study? 
You may or may not personally benefit from your participation in this study. You may 
experience improved healing in your burn wound and have less of a chance of developing an 
infection; however, this is not guaranteed. This study may help us to understand how 
SynePure Wound Cleanser and Catasyn Advanced Technology Wound Hydrogel compares 
to the standard of care (Silvadene) in terms of safety and effectiveness. 
Alternative Treatments 
If you choose not to participate in the study, this will not affect your treatment or care at the 
UPMC Mercy Burn Center.  The center physicians will apply the current recommended 
treatment for a superficial partial-thickness burn following their standard of care treatment 
protocol. 
You will be promptly notified if any new information we learn during this research study 
that may cause you to change your mind about continuing to participate in the study. 
Will I or my insurance provider be charged for the costs of any procedures performed 
as part of this research study?  
Some of the services or items in this study are part of the regular treatment for your burn. 
These services would be performed or used even if you were not in this study. The costs for 
these services or items will be billed to your insurance. You will be responsible for any costs 
your insurance does not cover. If you have any questions about these costs, or what out-of-
pocket expenses you may be responsible for, contact your insurance company. If you are 
uninsured, you will be responsible for these costs.  
The study treatments (either SynePure Wound Cleanser and Catasyn Advanced Technology 
Wound Hydrogel OR Silvadene) will be provided at no cost to you. 
Will I be reimbursed if I take part in this research study?  
You will receive compensation for your research visits to defray the cost of parking, should 
the visit exceed 2 hours in duration. You may be reimbursed up to a total of $40.00 for 
completion of the research visits (Visits 3, 4, 6, and 7). This reimbursement will be in the 
form of a $10.00 loaded onto a University Vincent Mastercard for each of these completed 
research visits.  Should your research visits be completed through telemedicine, you will not 
receive compensation for parking. 
Who will pay if I am injured as a result of taking part in this research study?  
If you believe that the research procedures have resulted in an injury to you, immediately 
contact Dr. J. Peter Rubin who is listed on the first page of this form. Emergency medical 
treatment for injuries solely and directly related to your participation in this research study 
will be provided to you by the hospitals of UPMC. Your insurance provider may be billed 
for the costs of this emergency treatment, but none of those costs will be charged directly to 
you. If your researchrelated injury requires medical care beyond this emergency treatment, 


 
            
                             
 
22
you will be responsible for the costs of this follow-up care.  Currently, there is no plan for 
any additional financial compensation. You waive no legal rights by signing this consent. 
Who will know about my participation in this research study?  
To protect the confidentiality of information we obtain from you and your medical records, 
we will keep all information about you in a secure location. All paper records that could 
identify you will be stored in locked file cabinets, and all electronic records will be stored in 
passwordprotected files. Access to this information will be limited to research team 
members and to those health care professionals who are providing clinical services as part of 
this research study.  
Will this research study involve the use or disclosure of my identifiable medical 
information?  
As part of this study, we are also requesting your permission to review your medical records 
to obtain past, current, and future medical information from hospitals and other medical 
facilities. We will obtain information concerning your diagnosis, age, past medical history, 
diagnostic or surgical procedures that may have been done as part of your care for your burn 
and any associated injuries you may have experienced. Should we receive this information, 
we may use this information to determine whether you meet the conditions for participation 
in this study. 
Although we will do everything in our power to protect your privacy and confidentiality of 
your records, just as with the use of your medical information for health care purposes, we 
cannot guarantee the confidentiality of your research records, including information that we 
obtained from your medical records. This research study will result in identifiable 
information that will be placed into your medical records held at UPMC, namely this 
consent form.  
Per University of Pittsburgh policy all research records must be maintained for at least 7 
years following final reporting or publication of a project. Data resulting from this research 
study may be shared with other investigators in the future, and all information will be de-
identified prior to the sharing of this information. 
Who will have access to identifiable information related to my participation in this 
research study? 
This identifiable information will be made available to members of the research team for an 
indefinite period of time. That medical information, as well as information obtained during 
this research study, may be shared with other groups including authorized officials from the 
Department of Defense or Synedgen, the Food and Drug Administration (FDA), the 
University of Pittsburgh Human Research Protection Office (HRPO), and authorized 
representatives of the UPMC hospitals or other affiliated health care providers may have 
access to your identifiable information (which may include your identifiable medical 
information) related to your participation in this research study for the purpose of: 
(1) fulfilling orders, made by the investigators, for hospital and health care services 
(e.g., laboratory tests, diagnostic procedures) associated with research study 
participation; (2) addressing correct payment for tests and procedures ordered by the 
investigators; and/or  
(3) assessing internal hospital operations (i.e. quality assurance).  


 
            
                             
 
23
Any information that is entered into your medical records will be available to you, in 
accordance with the UPMC Notice of Privacy Practices. 
Authorized representatives of US and foreign government regulatory agencies such as the 
U.S.  
Food and Drug Administration (FDA) may review and or obtain your identifiable 
information (which may include your identifiable medical record information) related to 
your participation in this research study for the purpose of monitoring the accuracy of the 
research data. While these agencies understand the importance of maintaining the 
confidentiality of your identifiable research and medical record information, UPMC and the 
University of Pittsburgh cannot guarantee the confidentiality of this information after it has 
been obtained by them. 
Your doctor may also be involved as an investigator in this research study, but you are not 
under any obligation to participate in any research study offered by your doctor. Before 
agreeing to participate in this research study, or at any time thereafter, you may wish to 
discuss participation in this study with another health professional, to obtain a ‘second 
opinion’ about study participation. 
A description of this clinical trial will be available on www.clinicaltrials.gov, as required by 
U.S. Law. This website will not include information that can identify you. At most, the 
website will include a summary of the results. You can search this website at any time. 
  
Is my participation voluntary?  
Your participation in this research study is completely voluntary. You may want to discuss 
this study with your family and friends and your personal physician before agreeing to 
participate. If there are any words you do not understand, feel free to ask us. The 
investigators will be available to answer your current and future questions. 
Whether or not you participate in this research study, it will have no effect on the standard of 
care that you receive or your current or future relationship with the University of Pittsburgh, 
UPMC or its affiliated health care providers or health care insurance providers.  
May I withdraw, at a future date, my consent for participation in this research study? 
You can, at any time withdraw from this research study; you can also withdraw your 
authorization for us to use your identifiable medical information for the purposes described 
above. This means that you will also be withdrawn from further participation in this research 
study. Any identifiable research or medical information obtained as part of this study prior 
to the date that you withdrew your consent will continue to be used and disclosed by the 
investigators for the purposes described above. 
To formally withdraw from this research study, you should provide a written and dated 
notice of this decision to the principal investigator of this research study, Dr. J. Peter Rubin 
(412-3838080) at the address listed on the first page of this form or his research colleagues. 
Your decision to withdraw your consent for participation in this research study will have no 
effect on your current or future medical care at a UPMC hospital or affiliated health care 
provider or your current or future relationship with a health care insurance provider. If you 
decide to withdraw from study participation after you have received the study agent, you 


 
            
                             
 
24
will receive standard-ofcare treatment as applicable and have follow-up assessments 
collected to ensure your safety upon termination from study participation.  
If I agree to participate in this research study, can I be removed from the study 
without my consent?  
If the investigators feel that you cannot complete the study requirements safely (for example, 
you develop complications such as infection, require surgery for your burn, are hospitalized 
or the classification of your burn is now deemed to be more severe- progressed to a full 
partial- thickness or deep-thickness burn, or non-compliance), they may withdraw you from 
the study. At the time of your withdrawal, the investigator will discuss with you the 
appropriate and requested follow up based on the specific event. 
OPTIONAL CONSENT FOR PHOTOGRAPHS OF YOUR BURN WOUND 
The research team is requesting permission to photograph any and all portions of your burn 
wound. These photos may be used for medical education and training, publication, and 
media reports – and, in any mode of transmission, including and not limited to: print, email, 
television, internet, etc. Your identifiable features in these photographs will be blacked out 
(i.e., eyes, facial features, tattoos etc.), and the de-identified photo will be focused on your 
burn wound area. You are not required to give this permission and can refuse at any time 
after giving consent to these photographs being obtained.  
I consent to the photography, as described above:  
________________________________  
__________________  
Participant’s Signature  
I do NOT consent to the photography:  
Date  
______________________________     
___________________  
Participant’s Signature  
Date  
VOLUNTARY CONSENT FOR STUDY PARTICIPATION  
The above information has been explained to me and all of my current questions have 
been answered. I understand that I am encouraged to ask questions, voice concerns or 
complaints about any aspect of this research study during the course of this study, and that 
such future questions, concerns or complaints will be answered by a qualified member of the 
research team or by Dr. J. Peter Rubin, at 412-383-8080. I understand that I may always 
request that my questions, concerns or complaints be addressed to Dr. J. Peter Rubin. At any 


 
            
                             
 
25
time, I may also contact the Human Protection Advocate of the HRPO Office, University of 
Pittsburgh (1-866212-2668) to discuss problems, concerns, and questions; obtain 
information; offer input; or discuss situations in the event that the research team is 
unavailable. By signing this form, I agree to participate in this research study, and allow the 
use and disclosure of my medical record information for the purposes described above. A 
copy of this consent form will be given to me.  
________________________________  
Printed name of Participant  
________________________________  
__________________  
Participant’s Signature  
Date / Time  
INVESTIGATOR CERTIFICATION: 
I certify that I have explained the nature and purpose of this research study to the above-
named individual(s), and I have discussed the potential benefits and possible risks of study 
participation. Any questions the individual(s) have about this study have been answered, and 
we will always be available to address future questions, concerns or complaints as they arise. 
I further certify that no research component of this protocol was begun until after this 
consent form was signed. 
___________________________________                 __________________________ 
Licensed Physician-Investigator Signature                          Date/Time